Mirum Pharmaceuticals, Inc. (MIRM)

Market Cap	2.10B
Revenue (ttm)	307.03M
Net Income (ttm)	-99.81M
Shares Out	48.00M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	353,624
Open	42.11
Previous Close	42.09
Day's Range	41.40 - 44.08
52-Week Range	23.14 - 48.89
Beta	1.16
Analysts	Strong Buy
Price Target	57.00 (+30.47%)
Earnings Date	Nov 12, 2024

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRM
• Website: https://www.mirumpharma.com

Financial Performance

In 2023, Mirum Pharmaceuticals's revenue was $186.37 million, an increase of 141.85% compared to the previous year's $77.06 million. Losses were -$163.42 million, 20.5% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is $57.0, which is an increase of 30.47% from the latest price.

Price Target

$57.0

(30.47% upside)

Analyst Consensus: Strong Buy